Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

Objectives: This study aimed to assess the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting. Methods: We conducted a phase II randomized controlled trial in symptomatic (maximum 5 days) and asymptomatic patient...

Full description

Bibliographic Details
Main Authors: Els Tobback, Sophie Degroote, Sabine Buysse, Liesbeth Delesie, Lucas Van Dooren, Sophie Vanherrewege, Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, Elizaveta Padalko, Steven Callens, Marie-Angélique De Scheerder
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:International Journal of Infectious Diseases
Subjects:
Camostat
COVID-19
Efficacy
Neutralizing antibodies
Randomized controlled trial
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222003885

Similar Items

Similar Items